UK reviews medical technology use in heart failure diagnosis
This article was originally published in Clinica
Executive Summary
The UK's National Coordinating Centre for Health Technology Assessment (NCCHTA) has launched a comprehensive review of heart failure diagnostics in primary care, with the aim of developing an optimum strategy. A three-year research programme will aim to model the use of different combinations of tests, and will be based on, among other things, raw data from B-type natriuretic peptide (BNP) testing in primary care.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.